Welcome to Dwaey, specifically on Basiliximab page.
This medicine contains important and useful components, as it consists of
Basiliximab is available in the market in concentration.
Basiliximab
Before receiving Basiliximab, it is essential that patients consult with their healthcare provider, as there are several important precautions to consider:
- Infections: Basiliximab is an immunosuppressive medication, which may increase the risk of infections, including serious infections like bacterial, fungal, or viral infections. Patients should be monitored for any signs of infection, and any active infections should be treated before starting Basiliximab.
- Hypersensitivity Reactions: Patients with a history of hypersensitivity reactions (such as allergies to monoclonal antibodies) should inform their doctor. Although rare, severe allergic reactions (e.g., anaphylaxis) can occur, which may require immediate medical attention.
- Renal Impairment: While no dose adjustment is typically needed in patients with mild to moderate renal impairment, the use of Basiliximab in individuals with severe renal dysfunction should be approached with caution. Regular monitoring of kidney function is recommended during treatment.
- Pregnancy and Lactation: Basiliximab should be used during pregnancy only if the potential benefits outweigh the risks, as it is a monoclonal antibody and the safety in pregnant women has not been fully established. It is not known whether it passes into breast milk, so it is important to discuss the use of this medication during breastfeeding with your healthcare provider.
- Vaccinations: Patients receiving Basiliximab should avoid live vaccines, as immunosuppressive therapy can reduce the body’s ability to mount an immune response. It’s important to inform healthcare providers about any recent vaccinations or plans for vaccination.
Basiliximab is a monoclonal antibody used primarily for the following purposes:
- Prevention of Acute Renal Allograft Rejection: Basiliximab is used to prevent acute rejection in patients receiving a kidney transplant. It works by suppressing the immune response that can lead to the rejection of the transplanted kidney, enhancing the success of the transplant.
- Induction Therapy in Kidney Transplantation: It is often used as part of induction therapy in kidney transplant recipients, particularly when combined with other immunosuppressive agents, to suppress the initial immune response and allow the transplanted organ to establish itself.
- Off-label Use: Basiliximab may also be considered in other transplant-related indications or autoimmune conditions, though it is not commonly used for these purposes and requires clinical judgment by a healthcare provider.
Basiliximab should not be used in the following situations:
- Hypersensitivity to Basiliximab or Its Components: Basiliximab is contraindicated in patients who have shown a history of severe allergic reactions to the drug or any of its components, as these reactions can be life-threatening.
- Active Infections: Since Basiliximab suppresses the immune system, it is contraindicated in individuals with active systemic infections, as the body may not be able to effectively fight off the infection.
- Severe Immunosuppression: Basiliximab should be avoided in patients who are already severely immunosuppressed, as the additional suppression may increase the risk of serious infections and other complications.
Common and severe side effects of Basiliximab can occur, and it is important for patients to monitor for the following:
- Common Side Effects:
- Headache, fever, and chills are the most frequently reported side effects.
- Nausea, vomiting, and diarrhea can occur in some patients.
- Injection site reactions such as pain, redness, or swelling may be seen.
- Severe Side Effects:
- Serious infections: As Basiliximab suppresses the immune system, there is an increased risk of serious infections such as bacterial, fungal, or viral infections. Infections like pneumonia, sepsis, or urinary tract infections may develop.
- Anaphylaxis: A rare but potentially life-threatening allergic reaction characterized by difficulty breathing, swelling, and a drop in blood pressure. This requires immediate medical intervention.
- Liver Enzyme Elevation: Basiliximab has been associated with changes in liver enzymes, which may indicate liver dysfunction. Liver function tests should be monitored during treatment.
- Thrombocytopenia: A decrease in platelet count, which could increase the risk of bleeding. Platelet levels should be monitored regularly during treatment.
2
Basiliximab is a monoclonal antibody that specifically targets the IL-2 receptor (CD25) on the surface of T lymphocytes (T cells). The mode of action includes:
- T-Cell Suppression: Basiliximab binds to the alpha chain (CD25) of the IL-2 receptor on activated T cells. This prevents the receptor from binding to its natural ligand, interleukin-2 (IL-2), which is necessary for T cell activation, proliferation, and differentiation.
- Prevention of Allograft Rejection: By inhibiting the activation of T cells, Basiliximab helps to reduce the immune response that could lead to the rejection of the transplanted organ. This is particularly useful in kidney transplants, where the body might otherwise perceive the transplanted organ as foreign and attack it.
By targeting the IL-2 receptor, Basiliximab suppresses the early stages of immune activation that are involved in transplant rejection, enhancing the chances of a successful transplant.
Basiliximab can interact with several other medications, which may affect its efficacy or increase the risk of adverse effects. Some key interactions include:
- Immunosuppressive Drugs: Basiliximab is often used in combination with other immunosuppressive drugs (e.g., cyclosporine, tacrolimus, or mycophenolate mofetil) to prevent transplant rejection. Careful monitoring of drug levels and renal function is important, as these combinations can increase the risk of nephrotoxicity and other adverse reactions.
- Vaccines: Basiliximab can reduce the body’s ability to respond to live vaccines, so live vaccines should not be administered while on Basiliximab therapy. Inactivated vaccines may still be administered, but their efficacy should be monitored.
- Other Immunosuppressants: Basiliximab may enhance the effects of other immunosuppressive agents, leading to an increased risk of infections and malignancies. Careful titration and monitoring are essential to minimize these risks.
The recommended dosing of Basiliximab for adults is as follows:
- Prevention of Renal Allograft Rejection:
- Induction therapy: A typical dose is 20 mg administered as an intravenous (IV) infusion. The first dose is usually given within 2 hours before kidney transplantation, and the second dose is administered 4 days after transplantation.
- For most patients, a single dose regimen is sufficient. However, for high-risk patients, additional doses may be considered based on the clinical situation and the transplant center's protocol.
The use of Basiliximab in pediatric patients is similar to that in adults for kidney transplant recipients.
- The typical dose for children is 20 mg administered intravenously, with the first dose given within 2 hours before transplantation and a second dose 4 days post-transplant.
- As with adults, no major dose adjustments are required based on the child’s age, though careful monitoring for adverse reactions, such as infections and allergic responses, is necessary.
It is important to discuss the potential benefits and risks of Basiliximab therapy with a healthcare provider, especially for pediatric transplant patients.
There are no specific renal dose adjustments required for Basiliximab in patients with mild to moderate renal impairment. However, in patients with severe renal impairment or those on dialysis, special care should be taken when using Basiliximab. Regular monitoring of renal function and blood pressure is recommended throughout treatment, and adjustments to concomitant immunosuppressive therapies (like cyclosporine) may be necessary.
Not available in a medicine form yet